RVPH250417P5000
- 3.58
- 0.000.00%
Reviva Pharmaceuticals Newsroom
Reviva Pharmaceuticals: Promising Schizophrenia Treatment Drives Buy Rating
Express News | Reviva Pharmaceuticals Holdings Inc : Benchmark Cuts Target Price to $14 From $17
Roth MKM Reaffirms Their Buy Rating on Reviva Pharmaceuticals Holdings (RVPH)
10-K: FY2024 Annual Report
12 Health Care Stocks Moving In Tuesday's Intraday Session
Ulta Beauty To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Tuesday
Express News | D. Boral Capital Maintains Buy on Reviva Pharmaceuticals, Lowers Price Target to $8
Express News | Reviva Pharmaceuticals: Expects to Report Material Weaknesses in Internal Control Over Financial Reporting
Express News | Reviva Pharmaceuticals Holdings Files for Non-Timely 10-K - SEC Filing
Express News | Reviva Pharmaceuticals FY Net Income USD -29.9 Million
Express News | Reviva Pharmaceuticals FY EPS USD -0.9
Press Release: Reviva Reports Full Year 2024 Financial Results and Recent Business Highlights
Reviva Reports Full Year 2024 Financial Results and Recent Business Highlights
Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress
Reviva Pharmaceuticals Approves Executive Compensation Changes
Reviva to Participate in the 2025 BIO CEO & Investor Conference
H.C. Wainwright Maintains Reviva Pharmaceuticals(RVPH.US) With Buy Rating, Cuts Target Price to $7
Express News | D. Boral Capital Maintains Buy on Reviva Pharmaceuticals, Maintains $15 Price Target
Maxim Group Initiates Reviva Pharmaceuticals(RVPH.US) With Buy Rating, Announces Target Price $7
Maxim Group Upgrades Reviva Pharmaceuticals(RVPH.US) to Buy Rating, Announces Target Price $7